Our understanding of the genetic basis of predisposition to psoriasis is increasing exponentially due to the progress of genetic studies. However, so far little is known about genetic predisposition in relation to the response to psoriasis treatments. Recent data identified genetic predictors for the clinical outcome of conventional treatments such as methotrexate, acitretin and vitamin D derivatives, but few studies are available on genetic predictors of response to biologics. We hypothesized that genetic variations associated with increased risk of developing psoriasis may also act as predictors for the outcome of biologic therapy.

Talamonti, M., Botti, E., Galluzzo, M., Teoli, M., Spallone, G., Bavetta, M., et al. (2013). Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. BRITISH JOURNAL OF DERMATOLOGY, 169(2), 458-463 [10.1111/bjd.12331].

Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

Talamonti, M;Botti, E;Galluzzo, M;Spallone, G;Chimenti, S;
2013-08-01

Abstract

Our understanding of the genetic basis of predisposition to psoriasis is increasing exponentially due to the progress of genetic studies. However, so far little is known about genetic predisposition in relation to the response to psoriasis treatments. Recent data identified genetic predictors for the clinical outcome of conventional treatments such as methotrexate, acitretin and vitamin D derivatives, but few studies are available on genetic predictors of response to biologics. We hypothesized that genetic variations associated with increased risk of developing psoriasis may also act as predictors for the outcome of biologic therapy.
ago-2013
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Con Impact Factor ISI
Adult; Aged; Antibodies, Monoclonal, Humanized; Biological Products; Cornified Envelope Proline-Rich Proteins; DNA-Binding Proteins; Female; Gene Deletion; HLA-C Antigens; Humans; Interleukin-12; Interleukin-23; Male; Middle Aged; Polymorphism, Genetic; Psoriasis; Ustekinumab; Young Adult
Talamonti, M., Botti, E., Galluzzo, M., Teoli, M., Spallone, G., Bavetta, M., et al. (2013). Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. BRITISH JOURNAL OF DERMATOLOGY, 169(2), 458-463 [10.1111/bjd.12331].
Talamonti, M; Botti, E; Galluzzo, M; Teoli, M; Spallone, G; Bavetta, M; Chimenti, S; Costanzo, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Cw6 British.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 187.32 kB
Formato Adobe PDF
187.32 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/198131
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 128
  • ???jsp.display-item.citation.isi??? 119
social impact